[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Cuthbert, 1994 - Google Patents

Cystic fibrosis gene update.

Cuthbert, 1994

View PDF
Document ID
14651437645696963266
Author
Cuthbert A
Publication year
Publication venue
Journal of the Royal Society of Medicine

External Links

Snippet

It is now 4 years since the cystic fibrosis (CF) gene was cloned'-3. In the intervening period the function of the protein coded for by the gene (CFTR, cystic fibrosis transmembrane conductance regulator) has been significantly clarified. Even more importantly the first …
Continue reading at www.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Similar Documents

Publication Publication Date Title
Hay et al. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector
RU2145611C1 (en) Polypeptides showing activity of pulmonary surface-active substance and pharmaceutical composition
US5750571A (en) Methods and therapeutic compositions for treating cystic fibrosis
US5958893A (en) Genes and proteins for treating cystic fibrosis
JPH08503855A (en) Gene therapy for cystic fibrosis
CA2037478A1 (en) Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator
US6015828A (en) Chemical modification of chloride channels as a treatment for cystic fibrosis and other diseases
EP1997502A1 (en) Reconstituted surfactants having improved properties
EP0383837A1 (en) Alveolar surfactant proteins
JP2005053929A (en) Alveolar surfactant protein
US20240197921A1 (en) Signal peptides
EP3393489A1 (en) Synthetic lung surfactant with enhanced stability and effectiveness
Colledge Cystic fibrosis gene therapy
Cuthbert Cystic fibrosis gene update.
Welsh The path of discovery in understanding the biology of cystic fibrosis and approaches to therapy.
AU782051B2 (en) Enhanced delivery via serpin enzyme complex receptor
AU7974194A (en) Deoxyribonucleic acids containing inactivated hormone responsive elements
Kitson et al. Gene therapy for cystic fibrosis
CA2186242A1 (en) Gene-therapeutic process using antibiotic-resistance gene-free dna vectors
US6468793B1 (en) CFTR genes and proteins for cystic fibrosis gene therapy
Feuerbach et al. Progress in human gene therapy
US20070053879A1 (en) Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator
JP2001503257A (en) IL-12 gene expression and delivery systems and uses
Ko et al. Frontiers in research on cystic fibrosis: understanding its molecular and chemical basis and relationship to the pathogenesis of the disease
Alton et al. New treatments for cystic fibrosis